Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

PHASE4RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Partial Lipodystrophy
Interventions
DRUG

Metreleptin

Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

Trial Locations (12)

Unknown

RECRUITING

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille

RECRUITING

Hopital Pitie-Salpetriere, Paris

RECRUITING

Hôpital Saint-Antoine, Paris

RECRUITING

Centre Hospitalier Lyon-Sud, Pierre-Bénite

RECRUITING

Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM), Berlin

NOT_YET_RECRUITING

Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin, Ulm

RECRUITING

Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna

NOT_YET_RECRUITING

"Universitá degli Studi Magna Graecia di Catanzaro", Catanzaro

RECRUITING

Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara

RECRUITING

Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello, Pisa

RECRUITING

A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia, Udine

NOT_YET_RECRUITING

Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amryt Pharma

INDUSTRY